A first result of that partnership is a three year deal with the Clinical Research Department of the Singapore General Hospital (SGH). SGH will apply the Genomatix Chip Analysis pipeline to their Affymetrix based expression studies.
"I am very excited about this partnership with RI", says Klaus May, Director of Sales & Marketing at Genomatix. "Beyond other technologies, RI is one of the strongest providers of Affymetrix chips and services in this area. With our ChipInspector and GenomatixSuitePE products, now RI is a one-stop-shop for providing latest science, technology and services in South East Asia.", he continues.
Research Instruments Pte Ltd is a leading distributor of instruments, supplies and reagents for the analytical and research laboratories. RI represents industry leading manufacturers in providing next-generation tools and techniques together with services including training, maintenance, development of analysis methods and instrument validation.
Established in Singapore in 1989, Research Instruments Singapore employs approximately 30 people including catering to our customers in the fields of life science research, pharmaceutical, chemical, environmental, agricultural and material science. RI has sister companies in Malaysia, Thailand, Australia, New Zealand and a selection of dealers throughout S.E. Asia.
Genomatix is a pioneer and leader in the analysis and understanding of eukaryotic gene regulation. Technological leadership is complemented by a microarray analysis pipeline. This unique Genomatix-strategy and product integration allows efficient handling of low level analysis from raw expression data (e.g. CEL files), pathway/network analysis, biological classification and identification of the molecular basis for co-regulation on gene promoter level. All Genomatix tools for each step of the analysis have been awarded the Affymetrix GeneChip-compatible status. The integrated Genomatix approach allows unparalleled analysis of the full potential of microarray data and generates new knowledge concerning the biological mechanisms involved by superimposing pathway and sequence information. In addition, the analysis time has been drastically reduced, resulting in a significantly enhanced ROI for microarray experiments. Genomatix has published more than 170 peer reviewed scientific papers that have been cited in more than 4,000 papers. Over 27,000 researchers worldwide currently apply Genomatix tools and databases.
Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.